Blood substitutes short answer for muhs pg exam
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive material from three major surgery/emergency medicine textbooks. Let me compile the structured short-answer response for the MUHS PG exam.
Blood Substitutes
Short Answer for MUHS PG Exam
Definition
Blood substitutes are fluids capable of carrying and delivering oxygen to tissues, developed as an alternative to allogeneic red blood cell (RBC) transfusion.
(Sabiston Textbook of Surgery)
Why Are They Needed?
- Limited blood supply and short shelf life of stored RBCs
- Risk of transfusion-transmitted infections (HIV, hepatitis, etc.)
- Transfusion reactions (ABO/Rh incompatibility)
- Lack of blood in rural, austere, or combat settings
- Patients who refuse transfusion (e.g., Jehovah's Witnesses)
Ideal Properties of a Blood Substitute
- Delivers oxygen efficiently
- Compatible with all blood types (no crossmatch needed)
- Few or no side effects
- Prolonged storage capability (at room temperature)
- Persists in circulation
- Cost-effective
- Pathogen-free
(Sabiston; Roberts & Hedges' Clinical Procedures in Emergency Medicine)
Classification
Blood substitutes are broadly of two types:
1. Biomimetic (Haemoglobin-Based)
These mimic the oxygen-carrying capacity of blood.
A. Haemoglobin-Based Oxygen Carriers (HBOCs)
Also called "stromal-free haemoglobin solutions."
Sources of Hb:
- Outdated donated human RBCs
- Bovine (cow) blood
- Transgenic E. coli (recombinant Hb)
Why not free Hb?
Free (unmodified) haemoglobin is toxic - it causes:
- Osmotic diuresis and renal tubular toxicity
- Coagulation abnormalities
- Vasoconstriction (by scavenging nitric oxide)
- Short half-life in circulation
Modifications to stabilize Hb:
| Method | Mechanism |
|---|---|
| Cross-linking | Links tetramer subunits for stability |
| Polymerization | Increases molecular mass (~130 kDa) - less vasoconstriction, longer circulation |
| Encapsulation in liposomes | Mimics RBC; similar O₂ dissociation curve |
| Microsphere technology | Forms millions of stable micromolecules |
Current-generation HBOCs (2nd generation):
- Pasteurized - free of communicable pathogens
- No ABO/Rh antigens - universally compatible
- No blood banking required
- Remaining side effects: free radical generation, methemoglobin production, immunosuppression, NO scavenging causing vasoconstriction
Notable products:
- HemAssist (DCLHb) - Diaspirin cross-linked Hb by Baxter. Trial stopped early due to higher 28-day mortality (47% vs 25% with saline) in traumatic hemorrhagic shock.
- Hemopure (HBOC-201) - Bovine polymerized Hb; stable at room temperature for 3 years; approved in South Africa and Russia; increased serious adverse events (MI) due to vasoconstrictive properties.
- HemO2life - Polymerized extracellular Hb from the marine polychaete Arenicola marina; approved in EU for donor organ preservation before transplantation.
Concern from meta-analysis: A meta-analysis of 16 HBOC trials showed a significantly increased risk of myocardial infarction and death compared with controls - primarily due to vasoconstriction from NO scavenging.
3rd-generation HBOCs: Hb encapsulated in liposomes (similar O₂ dissociation curve to native RBCs) - still being optimized.
2. Abiotic (Non-Haemoglobin Based)
B. Perfluorocarbons (PFCs)
- Totally synthetic carbon-fluorine compounds
- High oxygen-dissolving and CO₂-dissolving capacity (passive physical dissolution, not chemical binding)
- Not miscible with water - must be emulsified for intravenous administration
- Advantages: unlimited supply, chemically stable, no infection risk, no compatibility issues
- Disadvantages: short half-life (degrades within 48 hours), require high inspired FiO₂, must be emulsified
- 2nd-generation PFC emulsions showing potential in clinical trials
Summary Comparison Table
| Feature | HBOCs | Perfluorocarbons |
|---|---|---|
| Mechanism | Carries O₂ via Hb | Dissolves O₂ physically |
| Source | Human/Bovine/Recombinant | Synthetic |
| Compatibility | Universal (no crossmatch) | Universal |
| Shelf life | 1-4 years | Short (~48 h after admin) |
| Infection risk | Low (pasteurized) | None |
| Main side effect | Vasoconstriction (NO scavenging), MI | Requires high FiO₂ |
| Storage | Room temperature | Requires emulsification |
Current Status
- No blood substitute is currently approved for routine clinical use in India or the USA.
- HBOCs remain investigational in most countries; Hemopure is approved in South Africa and Russia for compassionate use.
- Areas with greatest benefit: combat/trauma settings, remote areas, patients refusing transfusion.
(Sources: Bailey & Love's Short Practice of Surgery 28th ed.; Sabiston Textbook of Surgery; Roberts & Hedges' Clinical Procedures in Emergency Medicine)
This is a shared conversation. Sign in to Orris to start your own chat.